Clinical Study of Visibility Tinted Clariti Contact Lens

Sponsor
Sauflon Pharmaceuticals Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT01996787
Collaborator
(none)
38
1
2
3
12.6

Study Details

Study Description

Brief Summary

The purpose of this study was to investigate the safety and efficacy of the Sauflon Clariti Monthly silicone hydrogel contact lenses with handling tint (Sauflon Pharmaceuticals Limited) by comparison with Air Optix Aqua silicone hydrogel lenses (Alcon Inc.)

Subjects used OptiFree Replenish solution (Alcon Lboratories Inc.) for daily lens maintenance, care and storage.

Condition or Disease Intervention/Treatment Phase
  • Device: Air Optix Aqua
  • Device: Clariti with Handling Tint
N/A

Detailed Description

I. Study characteristics:

The clinical study evaluates the clinical performance of a silicone hydrogel contact lens for daily wear, Clariti (including handling tint) (Sauflon Pharmaceuticals Ltd.) versus a predicate device, Air Optix Aqua (Alcon Inc.), in terms of lens performance, physiological response and subjective acceptance.

Subjects used OptiFRee Replenish solution (Alcon Laboratories Inc.) for daily lens maintenance, care and storage.

The key features were as follows:
  1. One month duration.

  2. Three investigator sites.

  3. Daily wear soft (hydrophilic) silicone hydrogel contact lenses, replaced on a monthly basis: Clariti Monthly (with handling tint)and Air Optix Aqua. Replenish was used as a care system by all subjects.

  4. A total of 38 subjects were enrolled, and 38 subjects accounted for 76 eyes were dispensed lenses. This group was randomized into 25 test subjects (50 eyes) and 13 control subjects (26 eyes).

  5. Of the 25 test subjects, 25 (100%) completed one month of use. Of the 13 control subjects, 12 (92.3%)completed one month of use.

  6. There were no adverse reactions.

II. Study period:

The study was conducted over one month of wear. Subjects were examined initially, and at two follow-up visits after two weeks and four weeks respectively. Study visits commenced on June 26, 2013 and completed on September 14, 2013.

Study Design

Study Type:
Interventional
Actual Enrollment :
38 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Official Title:
The Clinical Performance of the Clariti Contact Lens (Including Handling Tint) for Daily Wear
Study Start Date :
Jun 1, 2013
Actual Primary Completion Date :
Jul 1, 2013
Actual Study Completion Date :
Sep 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Air Optix Aqua

Compare safety and efficacy of the lens using OptiFree Replenish solution

Device: Air Optix Aqua
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Device: Clariti with Handling Tint
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Active Comparator: Clariti with Handling Tint

Compare safety and efficacy of the lens using OptiFree Replenish solution

Device: Air Optix Aqua
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Device: Clariti with Handling Tint
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Outcome Measures

Primary Outcome Measures

  1. Slit lamp Biomicroscopy [1 month]

    Slit Lamp examination will be performed at the initial and follow-up visits. Slit lamp findings will be graded on a 0-4 scale (0=none;4=severe).

  2. Adverse reactions [1 month]

    Adverse reactions will be recorded throughout the study. Adverse recations will be classified as serious, significant and non-significant.

  3. Wear Time [1 month]

    Lens wear time is recorded for the two study lenses at follow-up visits.

  4. Visual Acuity [1 month]

    LogMAR Visual Acuity at high contrast will be recorded before and after performeing an over-refraction at the initial, two-week and one-month visits.

Secondary Outcome Measures

  1. Subjective Scores [1 month]

    Subjective scores for comfort, vision, handling and overall score will be recorded at the initial and follow-up visits. The subjective scores will be graded on a 0-5 scale.

  2. Symptoms, problems and complaints [1 month]

    The presence or absence of symptoms, problems and complaints will be recorded at two-weeks and one-month visits.

  3. Discontinuations [1 month]

    All subjects discontinuations will be recorded at the two-week and one-month visits.

  4. Refraction [1 month]

    Refraction was undertaken and recorded for all subjects at the initial, two-weeks and one-month visits.

  5. Keratometry [1 month]

    Keratometry measures will be performed at the initial and one-month visits for all subjects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 56 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • They are 18 years of age and above

  • They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent

  • They are willing and able to follow the protocol

  • The agree not to paticipate in other clinical research for the duration of this study

  • They have a best spectacle corrected visual acuity greater or equal to 20/25 (logMAR 0.1)

  • They have a manifest cylinder less than or equal to 0.75D

  • They have successfully worn contact lenses within six months of starting the study

  • They can be fitted with spherical soft contact lenses within the power range available

  • They are willing to wear the study lenses for a minimum of four days a week, six hours a day

Exclusion Criteria:
  • They have any active anterior segment ocular disease which would normally contraindicate contact lens wear

  • They have any anterior segment infection, inflammation or abnormality

  • They use any systemic medications which would normally contraindicate contact lens wear

  • They are using any ocular medications

  • They have a history of herpetic keratitis

  • They have a systemic disorder which would normally contraindicate contact lens wear

  • They have any infectious disease (e.g. Hepatitis) or any immunosuppressive disease (e.g. HIV)

  • They have glaucoma (high pressure in the eye), have had cataract surgery or a history of recurring abrasions

  • They have had corneal refractive surgery or they have an irregular cornea

  • They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus

  • They are pregnant or lactating

  • They have any slit lamp findings which are more serious than grade 1

  • They have a history of anaphylaxis or severe allergic reactions

  • They have taken part in any other contact lens or contact lens care product clinical trial or research, within two weeks prior to starting this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eurolens Research Faculty of Life Sciences The University of Manchester Manchester United Kingdom M60 1QD

Sponsors and Collaborators

  • Sauflon Pharmaceuticals Ltd

Investigators

  • Principal Investigator: Philip Morgan, PhD, MCOptom FAAO FBCLA

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Sauflon Pharmaceuticals Ltd
ClinicalTrials.gov Identifier:
NCT01996787
Other Study ID Numbers:
  • S13-540
First Posted:
Nov 27, 2013
Last Update Posted:
Nov 27, 2013
Last Verified:
Nov 1, 2013
Keywords provided by Sauflon Pharmaceuticals Ltd
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 27, 2013